China approves commercial use of brain-computer interface devices

The brain-computer interface (BCI) industry is expanding globally, with China becoming the first country to approve the commercial use of BCI devices. Beijing has designated this technology as a strategic sector in its five-year plan. Notably, Tianjin-based Tiankai Suishi Intelligent Technology has received market approval for a multi-electrode headset designed to help doctors assess and diagnose cognitive functions.

As these technologies advance, insurance companies have begun announcing commercial policies to cover the invasive surgeries required for implantation. This development follows the trajectory set by companies like Elon Musk’s Neuralink, which aims to create a symbiotic relationship between humans and artificial intelligence.

However, the rise of experimental neural devices brings significant ethical and logistical challenges. As clinical trials conclude, questions arise regarding the long-term support of participants. There is currently no universal standard for whether patients can continue using devices ‘off-label’ or if they must have them removed once a trial ends, particularly when sponsors lack the funding for lifelong device maintenance.